Gilead Sciences Inc. Common Stock (GILD)
Stock · NASDAQ · Health Care
$156.19as of 10/16/2026
Price chart
Active signals
GILD Signal Track Record
How signals performed across all stocks →What GILD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 31 | +0.2% | 52% | September 4, 2026 |
| Bollinger Band Breakout | 29 | -0.8% | 48% | August 13, 2026 |
| 200-Day Moving Average TouchActive now | 19 | +1.8% | 58% | August 5, 2026 |
| Bollinger Band Breakdown | 16 | +0.4% | 56% | June 2, 2026 |
| Any 20-session window (baseline) | +1.1% | 58% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary bi…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 17,000
- Website
- www.gilead.com
Fundamentals
- 1-day range
- $146.1$151.44
- Market cap
- $162.47B
- P/E (trailing)
- —
- P/E (forward)
- 15.24
- EPS (trailing)
- $-2.66
- Dividend yield
- 3.98%
- Beta
- 0.40
- Avg. volume
- 5.98M
- Ex-dividend date
- September 15, 2026
- Dividend pay date
- September 29, 2026
How Gilead Sciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
26 analyst ratings
Gilead Sciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- GILDGilead Sciences Inc. Common Stock$156.19▼ 0.75%Market cap $162.47BP/E —$114.02$157.29
- AMGNAmgen Inc. Common Stock$432.49▼ 0.35%Market cap $218.50BP/E 26.35$288$447.03
- ARGXargenx SE American Depositary Shares$819.14▼ 3.21%Market cap $54.32BP/E 21.26$568.4$925
- RVMDRevolution Medicines Inc. Common Stock$177.96▼ 5.97%Market cap $42.05BP/E —$47.45$224.31
- BIIBBiogen Inc. Common Stock$232.65▼ 1.15%Market cap $30.48BP/E 42.27$138$238.24
- BNTXBioNTech SE American Depositary Share$87.71▼ 2.76%Market cap $22.91BP/E —$79.52$124
- MRNAModerna Inc. Common Stock$218.01▼ 7.82%Market cap $21.50BP/E —$22.28$227.46
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GILD Gilead Sciences Inc. Common Stock | $162.47B | — | $156.19 | ▼ 0.75% | $114.02$157.29 |
| AMGN Amgen Inc. Common Stock | $218.50B | 26.35 | $432.49 | ▼ 0.35% | $288$447.03 |
| ARGX argenx SE American Depositary Shares | $54.32B | 21.26 | $819.14 | ▼ 3.21% | $568.4$925 |
| RVMD Revolution Medicines Inc. Common Stock | $42.05B | — | $177.96 | ▼ 5.97% | $47.45$224.31 |
| BIIB Biogen Inc. Common Stock | $30.48B | 42.27 | $232.65 | ▼ 1.15% | $138$238.24 |
| BNTX BioNTech SE American Depositary Share | $22.91B | — | $87.71 | ▼ 2.76% | $79.52$124 |
| MRNA Moderna Inc. Common Stock | $21.50B | — | $218.01 | ▼ 7.82% | $22.28$227.46 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Why Is Everyone Ignoring Gilead Stock's High Cash Yield?Yahoo · 10/10/2026
- Gilead Sciences (GILD) Laps the Stock Market: Here's WhyYahoo · 10/9/2026
- Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)Yahoo · 10/8/2026
- What Is Cognizant Technology Solutions (CTSH) Signaling With Its Latest AI Push?Yahoo · 10/8/2026
- RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126Benzinga · 10/8/2026
- Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price TargetBenzinga · 10/8/2026
- Is Extending the Gilead E3 Ligase Collaboration Altering The Investment Case For Nurix Therapeutics (NRIX)?Yahoo · 10/7/2026
- Is Exelixis Stock Engineered To Make You Money?Yahoo · 10/7/2026
Insider Activity
Insider Actions →- Daniel Patrick O'Day · October 1, 2026 · Sale3.0K @ $148.63
- Daniel Patrick O'Day · October 1, 2026 · Sale12.0K @ $147.72
- Burkhart Erin · September 22, 2026 · Option Exercise2.2K
- Burkhart Erin · September 22, 2026 · Tax Withholding768 @ $152.67
- Johanna Mercier · September 15, 2026 · Sale600 @ $145.29
- Johanna Mercier · September 15, 2026 · Sale800 @ $144.46
- Johanna Mercier · September 15, 2026 · Sale1.6K @ $143.69
- Andrew D. Dickinson · September 15, 2026 · Sale3.0K @ $145.29
- Wettan Keeley M. Cain · September 10, 2026 · Option Exercise590
- Wettan Keeley M. Cain · September 10, 2026 · Tax Withholding285 @ $144.81
- Johanna Mercier · September 10, 2026 · Option Exercise2.8K
- Johanna Mercier · September 10, 2026 · Tax Withholding1.3K @ $144.81
- Dietmar Berger · September 10, 2026 · Option Exercise533
- Dietmar Berger · September 10, 2026 · Tax Withholding263 @ $144.81
- Daniel Patrick O'Day · September 10, 2026 · Option Exercise8.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 989.59M
- Total value held
- $130.71B
- Institutional holders
- 2290
- Unknown119.01M
- Unknown80.65M
- Unknown71.91M
- Unknown59.86M
- Unknown41.28M
- Unknown29.73M
- Unknown27.13M
- Unknown26.25M
- Unknown24.25M
- Unknown23.30M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers
Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers. Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.